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Abstract
Background: Gender differences in short-term mortality in acute myocardial infarction (AMI) have been studied
extensively, whereas gender differences in long-term mortality and cause of death largely remain unknown. The
aim of this study was to assess the long-term risk of all-cause, cardiovascular and cancer death after AMI in women
compared to men.
Methods: Consecutive AMI patients were enrolled in a prospective registry between 2005 and 2011. Date and
cause of death were obtained by linkage with the Norwegian Cause of Death Registry, with censoring date 31
December 2012. AMI patients with ST-segment elevation (STEMI, n = 5159) and without (NSTEMI, n = 4899) were
analysed separately.
Results: The 5-years all-cause mortality rates in STEMI were 29% in women vs. 17% in men, and 42% vs. 29% in
NSTEMI, respectively. After adjustment for age and other confounders, women with STEMI had similar (HR 1.13
[95% CI: 0.98–1.32]) and women with NSTEMI lower (HR 0.82 [95% CI: 0.73–0.92]) risk of long-term all-cause mortality
compared to men. Competing-risks analysis showed no significant gender differences in age-adjusted risk of
cardiovascular death nor of cancer death. In both genders, the annual risk of cardiovascular death was low after
1 year, but exceeded annual risk of cancer death throughout follow-up.
Conclusion: During long-term follow-up, women with STEMI had similar and women with NSTEMI lower adjusted
risk of all-cause mortality compared to men. Age-adjusted risk of death due to cardiovascular disease was similar in
both genders and higher than risk of death due to cancer throughout the follow-up period.
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Background
Several studies have shown a higher risk of short-term
mortality after acute myocardial infarction (AMI) in
women compared to men [1–4], particularly among
younger women with ST-segment elevation myocardial
infarction (STEMI) [5–7]. Gender differences in survival
are observed also in AMI populations treated with per-
cutaneous coronary intervention (PCI) [8, 9]. In other
studies, the adjustment for age, cardiovascular (CV) risk
factors and treatment have attenuated or eliminated the
excess female risk of all-cause mortality [2, 10–13].
Thus, whether or not the underuse of evidence-based
treatment can explain the higher mortality in women is
an unsettled question.
Little is known about gender differences in all-cause
mortality during long-term follow-up of AMI patients
(>1 year). Furthermore, causes of death are sparsely doc-
umented. A recent study found a temporal switch from
predominantly cardiac to non-cardiac causes of death
after PCI over two decades [14]. Another observational
study suggested a high risk of cardiac death immediately
* Correspondence: sigrun.h@online.no
1Department of Cardiology, Oslo University Hospital Ulleval, Postboks 4950
Nydalen, 0424 Oslo, Norway
2University of Oslo, Postboks 1072 Blindern, 0316 Oslo, Norway
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kvakkestad et al. BMC Cardiovascular Disorders  (2017) 17:75 
DOI 10.1186/s12872-017-0508-3
after STEMI, but the risk of death from non-cardiac
causes such as cancer increased later during follow-up
[15]. Still, a prolonged risk of CV events after a myocardial
infarction (MI) have been documented [16], but whether
gender differences in causes of death exist during long-
term follow-up after AMI is unknown.
The aim of our study was to assess the risk of all-
cause mortality in women compared to men during
long-term follow-up after AMI, and to study whether
there are gender differences in CV and cancer mortality.
Methods
Study population
All consecutive AMI patients admitted to Oslo Univer-
sity Hospital (OUH) Ulleval between 1 September 2005
and 31 December 2011 were included in a local AMI
registry. Patients were referred to our tertiary centre,
with a 24/7 service for PCI, from the region of South-
Eastern Norway. The source population and method of
registration has been described previously [17]. In brief,
all patients admitted to OUH Ulleval alive or with on-
going cardiopulmonary resuscitation and diagnosed with
AMI were included in the study. The diagnosis of AMI
was based on current international criteria [18]. Patients
were categorised as STEMI or non-STEMI (NSTEMI)
based on their index electrocardiogram (ECG).
Data collection and variables
Predefined variables were registered into a case report
form by the responsible physician during hospital admis-
sion. Trained study personnel checked the report form
for completeness and errors before entering the data
into an electronic database. A cross check against the
hospital discharge register was performed monthly and
missing patients were included if they met the diagnostic
criteria for AMI [18]. In a random control sample of 200
registered patients, we found >95% correspondence
between registered data and the patient records, except
for two variables with estimated 8% erroneous values in
the registry that were not included in the regression ana-
lyses. The frequency of missing data was <7% for each
variable in the registry, except for the ‘smoker or ex-
smoker’ variable with 13% missing values.
Treatment and in-hospital mortality
The decision to perform coronary angiography and PCI
was made by the treating physician. Coronary angio-
grams were registered as normal, with atheromatosis, or
with significant stenosis defined as >50% narrowing of
the lumen in one main coronary vessel or in multiple
vessels (including left main stem stenosis). Relevant in-
hospital medications and complications, including all-
cause death, were registered.
Follow-up and cause of death
Date and cause of death was obtained by linkage of the
local database with the Norwegian Cause of Death
Registry containing vital status throughout 2012.
Patients were censored if they were alive at the closing
date 31 December 2012. Patients who had emigrated at
the time of our analyses were censored at the date of last
hospital contact (n = 80). In the competing-risks analysis
of cause-specific mortality, patients were censored if
alive at 31 December 2012 or if dead by other causes
than the cause-specific analysis. Follow-up time was
calculated from admission until censoring or death.
The Norwegian Cause of Death Registry has a 98%
coverage of the Norwegian population [19]. For all
deaths, a death certificate (paper form IS-1025B) with a
logical sequence from the underlying to immediate cause
of death must be completed by a doctor. A code from
the International Classification of Disease (ICD) system
is allocated to the diagnoses in the death certificate. Sub-
sequently the underlying cause of death is identified by
the IRIS computer program with the Automated Classi-
fication of Medical Entities (ACME) module, or by as-
sessment of a professional coder. CV death was defined
as death with underlying diagnoses corresponding to the
ICD-10 codes I00-I99, cancer death included cause of
death with code C00-C97, and death of other causes
included all other underlying causes of death.
Ethics
Establishment of the local AMI registry and conduction
of the study was approved by the Privacy Protection
Officer at OUH. The Norwegian Data Protection
Authority and the Ministry of Health and Care services
provided concession for data linkage with the Norwegian
Cause of Death Registry, with an exemption from the
requirement of patient consent. The study was submitted
to the Regional Committee for Medical Research Ethics
(REK), South-East. However, the need for ethics approval
from REK was waived according to national regulations
(Health Personnel Act §29b). Data were anonymized
before analysis.
Statistical analyses
This was a single-centre prospective cohort study. Only
the patient’s first admission between 1 September 2005
and 31 December 2011 was included in each cohort, so
the patient was the unit of our analysis. As previous
studies found an interaction between gender and type of
AMI in relation to mortality [2], we analysed the STEMI
and NSTEMI cohorts separately. The primary outcome
was all-cause mortality during follow-up, and secondary
outcomes were CV and cancer mortality during follow-up.
Differences between women and men in baseline
characteristics and treatment were assessed by the Chi-
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square test for categorical variables and median regres-
sion for continuous variables. Odds ratio (OR) of all-
cause in-hospital mortality in women compared to men
was calculated by logistic regression. Kaplan-Meier sur-
vival plots were computed and gender differences in
survival assessed with the log-rank test. The crude, age-
adjusted and multivariate adjusted hazard ratio (HR)
for all-cause mortality in women versus men were calcu-
lated by Cox proportional hazards regression. Candidate
covariates for the Cox model were age, pre-hospital resus-
citation, pre-hospital thrombolysis (STEMI cohort only),
previous MI, previous stroke, previous revascularisation,
previous peripheral arterial disease, prior hypertension,
smoking, diabetes mellitus, coronary angiography, PCI,
ventricular tachycardia (VT)/fibrillation (VF) >48 h,
cardiogenic shock, atrioventricular block 2nd-3rd degree,
atrial fibrillation, heart failure, antibiotic treatment,
gastrointestinal bleeding and in-hospital stroke. Smok-
ing was considered an important potential confounder,
and with 10% (STEMI) and 15% (NSTEMI) of values
missing, we used multiple imputation with 11 predic-
tors assumed to be associated with the smoking variable.
We tested for an interaction between continuous age and
gender in the multivariate Cox model for all-cause mor-
tality. We also compared the HRs for all-cause mortality
in women versus men stratified by age (<70 years vs
≥70 years), with a Wald test. The proportional hazards
assumption was assessed by plotting the estimated log-log
survival functions for men and women against time.
The cumulative incidence function for the probability
of cause-specific mortality was stratified by gender [20].
We created a stacked cumulative incidence plot to show
how the total probability of one was allocated between
all competing events in women and men, including the
possibility of survival during follow-up. The Fine-Gray
model [21] was applied to find the underlying sub-
distribution hazard ratio (sHR) for competing risks of
CV, cancer and other-cause mortality in women versus
men during follow-up. The sHRs are not cause-specific
hazards, but should be interpreted as a binary increased
or decreased probability of cause-specific death when
adjusted for covariates [22]. All tests were two-sided and
a p-value <0.05 was considered statistically significant.
Analyses were performed with STATA 13 (Statacorp LP,
Texas, USA). The study confines with the STROBE
(STrengthening the Reporting of OBservational studies




Out of 10 747 registered hospital admissions for AMI,
we identified 4899 patients with STEMI (median age
63 years, 25% women) and 5159 patients with NSTEMI
(median age 70 years, 34% women) (Fig. 1). Six patients
did not fulfill AMI criteria and 677 re-admissions during
the period were excluded. Due to typing error in the
identification key, six patients could not be linked to the
Cause of Death Registry and were lost to follow-up. Base-
line characteristics of the population are shown in Table 1.
Treatment and in-hospital mortality
Among STEMI patients, women were less likely to
undergo coronary angiography and PCI compared to men,
although the percentage receiving angiography was high
(>90%) in both genders (Table 2). Women with STEMI
were less likely to be treated with antiplatelet therapy,
beta-blockers and statins (See Additional file 1: Appendix
Table A1). A total of 104/1214 (8.6%) women died in hos-
pital versus 185/3685 (5.0%) of men (OR 1.77 [95% CI:
1.38–2.27]). The gender difference was eliminated after
adjustment (age-adjusted OR 1.08 [95% CI: 0.82–1.40]).
In the NSTEMI cohort, women were also less likely to
undergo coronary angiography and PCI (Table 2) and
less likely to receive treatment with antiplatelets and sta-
tins compared to men (See Additional file 1: Appendix
Table A1). A total of 109/1776 (6.1%) women and 144/
3383 (4.3%) of men died in hospital (OR 1.47 [95% CI:
1.14–1.90]). Again, the gender difference was eliminated
after adjustment (age-adjusted OR 0.86 [95% CI: 0.65–
1.13]). In-hospital complications are shown in Additional
file 2: Appendix Table A2.
Long-term mortality
In the STEMI cohort, 318/1214 (26%) of women and
568/3685 (15%) of men died during a median follow-up
of 1262 days (25th-75th percentile [p]: 673–1900). Fig. 2
shows Kaplan-Meier survival plots for women compared
to men. The unadjusted HR for all-cause mortality was
higher in women compared to men (Fig. 3). After adjust-
ment for age and other confounders, the risk of long-
term all-cause mortality was similar in both genders (ad-
justed HR 1.13 [95% CI: 0.98–1.32]). No gender-age
interaction was found (p interaction 0.31).
In the NSTEMI cohort, 631/1776 (36%) of women
and 830/3383 (25%) of men died during a median
follow-up of 1043 days (25th-75th p: 537–1695, Fig. 2).
The unadjusted HR for all-cause mortality was higher
in women compared to men, but after adjustment for
age and other confounders the risk was lower in
women (Fig. 3). No significant interaction was found
between continuous age and gender (p interaction
0.052). When stratifying patients into groups <70 and
≥70 years, we found no significant heterogeneity in the
association with all-cause mortality (adjusted HR for
women versus men <70 years 1.02 [95% CI: 0.77–1.36];
adjusted HR for patients ≥70 years 0.79 [95% CI: 0.70–
0.90], p = 0.11). The log-log estimated survival curves
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for men and women were roughly parallel for both
STEMI and NSTEMI patients, thus the proportional
hazards assumption was regarded valid.
Cause specific mortality
Among the 886 STEMI patients who died, CV disease
was the cause of death in 67% of patients. Ten percent
of women and 15% of men who died, died of cancer.
Figure 4 illustrates the stacked cumulative incidence of
CV, cancer and other causes of death as a function of
time and shows the relationship between the competing
causes of death. The calculated sHR confirms the ordering
of the cumulative incidence function-plot; women with
STEMI were at higher risk of CV mortality than men, but
Table 1 Baseline characteristics










Age, yearsa 71 (60–80) 61 (53–70) <0.0001 77 (65–85) 67 (57–77) <0.0001
Smoker/ex-smoker, n (%)b 642 (62.0) 2344 (69.8) <0.0001 731 (51.0) 1949 (66.1) <0.0001
Diabetes mellitus, n (%)b 163 (13.4) 465 (12.6) 0.469 323 (18.2) 659 (19.5) 0.246
Previous hyperlipidemia, n (%)b,c 148 (12.2) 421 (11.5) 0.468 207 (11.7) 461 (13.7) 0.041
Previous hypertension, n (%)b 521 (42.9) 1163 (31.6) <0.0001 892 (50.2) 1320 (39.0) <0.0001
Previous MI, n (%)b 145 (11.9) 492 (13.4) 0.198 439 (24.7) 956 (28.3) 0.006
Previous PCI or CABG, n (%)b 87 (7.2) 428 (11.6) <0.0001 267 (15.0) 838 (24.8) <0.0001
Previous stroke, n (%)b 95 (7.8) 183 (5.0) 0.0002 231 (13.0) 341 (10.1) 0.002
Family history, n (%)b,d 160 (13.3) 606 (16.4) 0.007 158 (8.9) 438 (13.0) <0.0001
Peripheral artery disease, n (%)b 60 (4.9) 143 (3.9) 0.112 121 (6.8) 258 (7.6) 0.276
MI Myocardial infarction, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting
a median (25th-75th percentile)
b (%) = percent of patients with available information, denominator may vary
c Hyperlipidemia defined as treatment with lipid-lowering drugs at time of admission
d Coronary artery disease before age 65 years in women, 55 years in men in 1st order relatives
Fig. 1 Flow chart. AMI: Acute myocardial infarction
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the risk of cancer mortality was similar for both genders
during follow-up. After adjustment for age, we found no
gender differences in risk of CV nor cancer mortality
during follow-up (Table 3).
Among the 1461 NSTEMI patients who died, CV dis-
ease was the cause of death in 58% of women and 54% of
men, while cancer was the cause of death in 12% of
women and 17% of men. Figure 4 illustrates the relation-
ship between the competing causes of death in NSTEMI
patients. After adjustment for age, there were no signifi-
cant gender differences in risk of CV mortality, but a non-
significant reduction of cancer mortality risk in women
(sHR 0.76 [95% CI: 0.56–1.03], p = 0.072) (Table 3).
In both STEMI and NSTEMI patients the risk of death
was highest the first year after AMI (Table 4). After 1
year, the annual CV mortality rate in STEMI was <2.5%
in women and <1.5% in men. In NSTEMI patients, the
annual CV mortality rate after 1 year was <4.5% in
women and <2.5% in men (Table 4). Furthermore, annual
CV mortality was higher than annual cancer mortality
in both genders throughout the follow-up period (Fig. 4
and Table 4).
Discussion
In this long-term follow-up of a large AMI cohort, the
main findings were: 1) Women with STEMI had similar
and women with NSTEMI better long-term survival
compared to men, when controlling for age and other
confounding factors. 2) There were no significant gender
Table 2 Treatment










Pre-hospital thrombolysis, n (%)a 105 (8.6) 429 (11.7) 0.004 - - -
Coronary angiography, n (%) 1115 (91.9) 3591 (97.5) <0.0001 1200 (67.6) 2925 (86.5) <0.0001
Normal vessels, n (%)b 21 (1.9) 52 (1.5) 0.307 157 (13.2) 114 (3.9) <0.0001
Atheromatosis, n (%)b 23 (1.9) 48 (1.3) 0.083 126 (10.6) 136 (4.7) <0.0001
One-vessel disease, n (%)b 539 (48.4) 1630 (45.5) 0.086 396 (33.2) 1145 (39.4) 0.0002
Multiple-vessel or LMS disease, n (%)b 530 (47.6) 1853 (51.9) 0.017 512 (43.0) 1513 (52.0) <0.0001
Missing angiogram, n (%)b 2 (0.2) 8 (0.2) NS 8 (0.7) 17 (0.6) NS
Primary PCI, n (%)c 808 (66.5) 2653 (72.0) 0.0003 - - -
All PCI, n (%) 936 (77.0) 3160 (85.7) <0.0001 524 (29.5) 1598 (47.2) <0.0001
CABG, n (%) 37 (3.0) 187 (5.1) 0.003 109 (6.1) 423 (12.5) <0.0001
Door to balloon-time, minutesd 38 (29–55) 36 (29–52) 0.043 - - -
Symptom to balloon-time, minutesd 270 (170–495) 245 (155–456) 0.001 - - -
Symptom to angiography, daysd - - - 2 (1–4) 2 (1–4) <0.0001
LMS Left main stem, PCI percutaneous coronary intervention, CABG Coronary artery bypass grafting
(%) = percent of patients with available information, denominator may vary
a Pre-hospital or in local hospital
b among patients who underwent coronary angiography
c PCI ≤ 12 h from onset of symptoms, without prior thrombolysis
d median (25th–75th percentile)
Fig. 2 Kaplan-Meier survival estimates of all-cause mortality
during follow-up
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differences in age-adjusted risk of CV nor cancer
mortality.
Long-term follow-up studies after AMI (>1 year) are
scarce, but needed. During seven years of follow-up, we
show a similar age-adjusted risk of death among women
and men with STEMI. A high proportion of both gen-
ders were treated invasively, probably contributing to
the similar long-term prognosis. These results are in ac-
cordance with a recent report from Italy showing simi-
lar 1-year mortality for women and men with STEMI
[12]. However, other studies of STEMI patients selected
for PCI have reported a worse 1-year prognosis in
women compared to men, even after adjustment for
age and other confounders [8, 9].
Women with NSTEMI had 18% lower risk of long-
term death compared to men, after multivariate adjust-
ment. Lower risk in women was found already after age-
adjustment, suggesting that age is the most important
confounding factor when comparing long-term survival
in NSTEMI women versus men. Our results correspond
well with data from Sweden, confirming a 1-year survival
benefit in NSTEMI women treated during 1998–2002
[24], but contradict several previous studies reporting no
gender differences in risk estimates of mortality among
NSTEMI patients [12, 13, 25, 26]. These studies differ
with regard to study population, study period and con-
founding factors considered, and a comparison is not
straightforward. In general, our study reflects contem-
porary treatment with a frequent use of invasive treat-
ment also in women, and a much longer follow-up than
most other studies. Explanations for better long-term
survival in NSTEMI women could be awareness of gen-
der differences in presentation and treatment of AMI
resulting in equal opportunities for women and men
[27], less extensive coronary artery disease [28] or lower
general risk burden compared to their male counterparts
[29]. Among NSTEMI women in our study, normal ves-
sels or non-significant coronary artery disease were more
prevalent than in men and gender differences in treat-
ment during hospitalization were present. Gender differ-
ences potentially exist in complete versus non-complete
revascularization, drug prescription patterns, such as
duration of dual antiplatelet therapy, drug compliance,
and clinical follow-up influencing prognosis. Information
about these factors were not available in our study, but
should be included in future studies of long-term out-
comes in women and men after AMI.
To our knowledge, this is the first study to elucidate
the relationship between gender and risk of cause-
specific mortality in an unselected AMI population.
Especially in ageing clinical cohorts, an increased risk of
non-CV death could influence the long-term prognosis
after AMI. We did not find any significant gender differ-
ences in long-term CV mortality after adjustment for
age. After 1 year, the annual CV death rate in STEMI
patients in our study was low (<1.5% in men and <2.5%
in women), but still higher than the annual cancer death
rate throughout the follow-up period. Our results cor-
respond to the results from a Danish study of PCI-
treated STEMI patients (mean age 63 years), finding that
cardiac risk beyond 30 days post-STEMI was low (<1.5%
per year) [15]. In a recent report from Sweden, AMI
patients (median age 74 years) who survived 1 year had
a 20% risk of non-fatal MI, stroke or CV death during
the next 36 months [16]. These studies along with our
results all confirm a long-term risk of CV mortality and
a continued need for focusing on secondary prevention
measures among AMI patients of both genders.
Our finding of a non-significant tendency towards
lower age-adjusted cancer mortality in NSTEMI women
Fig. 3 Relative risk of all-cause mortality during follow-up in women compared to men. Median follow-up, STEMI: 1262 days (25th–75th percentile:
673–1900), NSTEMI: 1043 days (25th–75th percentile: 537–1695). Multivariate adjusted: see Methods section
Kvakkestad et al. BMC Cardiovascular Disorders  (2017) 17:75 Page 6 of 10
compared to men needs further investigation. In Norway
and Europe, men experience a higher risk of death from
cancer compared to women [30, 31], and our results
could reflect a higher incidence of and mortality from
cancer in men diagnosed with AMI. The results of the
present study must be interpreted with caution due to
few cancer deaths and the relatively short follow-up
period in the setting of a non-cancer cohort. Further
studies are needed to register the prevalence and type of
cancer in AMI patients, and should be powered to
evaluate the risk of cancer death competing with cardiac
death during long-term follow-up.
Fig. 4 Risk of cause-specific mortality during follow-up in women and men. Stacked cumulative incidence plot. The figure illustrates how the total
probability of one was allocated between the competing events: a) Cancer death b) Other-cause death c) Cardiovascular death d) Survival during
follow-up
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The strengths of our study is a complete follow-up of
unselected AMI patients during a 7-year period. We
investigated three categories of cause of death, giving a
more detailed description of mortality after AMI. We
provide a descriptive analysis that indicate contemporary
equal opportunities for women and men treated with
AMI. Limitations were that several comorbid conditions,
such as cancer, renal disease, dementia, autoimmune-
and pulmonary diseases were not registered at inclusion,
and may have confounded mortality risk. Heart rate and
blood pressure was not registered. Follow-up did not
include quality of life or physical performance, which are
important measures of outcome after AMI. The causes
of death in this study were not determined by autopsy,
the gold standard for identifying the cause of death.
Finally, this was a single centre study from the largest
university hospital in Norway, being a referral hospital
for 1.5 million people in Eastern Norway. However, the
results are not necessarily generalizable to other
populations.
Conclusion
After adjustment for age and other confounding factors,
women with STEMI had similar and women with
NSTEMI had better long-term prognosis compared to
Table 3 Competing risks regression. Sub-distribution hazard ratios of cause-specific mortality during follow-up
Unadjusted SHR (95% CI) p-value Age-adjusted SHR (95% CI) p-value
STEMI n = 4899
Cardiovascular death
Women versus men 1.76 (1.49–2.08) <0.0001 1.03 (0.87–1.22) 0.750
Cancer death
Women versus men 1.20 (0.80–1.79) 0.378 0.79 (0.51–1.22) 0.286
Other-cause death
Women versus men 2.21 (1.63–2.99) <0.0001 1.26 (0.91–1.74) 0.171
NSTEMI n = 5159
Cardiovascular death
Women versus men 1.63 (1.42–1.87) <0.0001 0.97 (0.84–1.12) 0.659
Cancer death
Women versus men 0.97 (0.74–1.29) 0.852 0.76 (0.56–1.03) 0.072
Other-cause death
Women versus men 1.52 (1.26–1.84) <0.0001 0.90 (0.74–1.10) 0.308
SHR Sub-distribution hazard ratio, CI Confidence interval







STEMIa Women Men Women Men Women Men
1 year 16.2 (14.3–18.4) 9.2 (8.3–10.1) 12.9 (11.1–15.0) 7.6 (6.8–8.5) 0.7 (0.4–1.4) 0.6 (0.4–0.9)
2 years 20.4 (18.2–22.8) 10.9 (10.0–12.0) 15.1 (13.2–17.3) 8.6 (7.7–9.5) 2.0 (1.3–3.1) 1.1 (0.8–1.5)
3 years 23.0 (20.7–25.6) 13.0 (12.0–14.2) 16.4 (14.4–18.7) 9.6 (8.7–10.6) 2.8 (1.9–4.2) 1.7 (1.3–2.2)
4 years 26.4 (23.8–29.2) 15.3 (14.1–16.6) 18.4 (16.2–20.9) 10.5 (9.5–11.6) 3.6 (2.5–5.1) 2.4 (1.9–3.0)
5 years 28.6 (25.8–31.6) 17.1 (15.8–18.6) 19.5 (17.1–22.2) 11.3 (10.2–12.5) 3.8 (2.7–5.5) 3.0 (2.4–3.8)
NSTEMIb Women Men Women Men Women Men
1 year 18.6 (16.9–20.5) 13.6 (12.5–14.8) 12.5 (11.0–14.2) 8.4 (7.5–9.4) 2.0 (1.4–2.8) 2.0 (1.6–2.6)
2 years 25.2 (23.2–27.3) 17.3 (16.0–18.6) 16.2 (14.5–18.0) 10.6 (9.6–11.7) 3.5 (2.7–4.6) 2.8 (2.3–3.5)
3 years 31.9 (29.6–34.2) 21.3 (19.9–22.8) 20.4 (18.5–22.6) 12.4 (11.2–13.6) 4.7 (3.7–6.0) 4.0 (3.3–4.9)
4 years 36.7 (34.3–39.3) 25.2 (23.6–26.8) 23.3 (21.1–25.6) 14.3 (13.0–15.7) 5.5 (4.3–7.0) 5.0 (4.2–6.0)
5 years 42.0 (39.2–44.9) 29.3 (27.5–31.2) 26.2 (23.7–29.0) 16.4 (14.9–18.0) 5.7 (4.5–7.3) 6.3 (5.2–7.5)
CI Confidence interval
aWomen n = 1214. Men n = 3685. Median (25th-75th percentile) follow-up: 1262 (673–1900) days
bWomen n = 1776. Men n = 3383. Median (25th-75th percentile) follow-up: 1043 (537–1695) days
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men. There were no significant gender differences in risk
of CV nor cancer death during follow-up. After one year,
annual risk of CV death in both genders was low, but still
exceeded annual risk of death due to cancer. Possible gen-
der differences in long-term risk of cancer death in AMI
patients need further investigation.
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